OmniSeq Offers Differentiating Platform to Clinically Detect Rare Genetic Alterations to Identify Patients Eligible for New, Targeted Therapy for Lung and Thyroid Cancer

On June 29, 2020 OmniSeq, an innovator in next generation sequencing (NGS) in oncology, reported the benefits of its OmniSeq Advance comprehensive genomic and immune profiling assay to detect the presence of rare alterations in the RET gene in the tumors of some patients with non-small cell lung cancer (NSCLC) and thyroid cancer (Press release, OmniSeq, JUN 29, 2020, View Source [SID1234561571]). Those patients eligible for treatment with Eli Lilly and Company’s recently FDA-approved selective RET kinase inhibitor Retevmo* (selpercatinib).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Retevmo is the first FDA-approved therapy specifically for cancer patients with fusions or mutations in the RET (rearranged during transfection) gene. OmniSeq Advance delivers the distinct advantage of using two technologies; RNA-sequencing for RET fusions and DNA-sequencing for RET mutations to provide optimal, comprehensive testing for Retevmo. OmniSeq Advance was one of the tests that could qualify a patient for enrollment to the LIBRETTO-001 Retevmo (selpercatinib) clinical trial.

The National Comprehensive Cancer Network (NCCN) recommends for NSCLC that when feasible, testing be performed via a broad, panel-based approach, most typically performed by next generation sequencing. For patients who, in broad panel testing don’t have identifiable driver oncogenes (especially in never smokers), consider RNA-based NGS if not already performed, to maximize detection of fusion events.

"OmniSeq Advance offers significant advantages for detecting RET fusions by RNA-sequencing as opposed to DNA-only sequencing," stated OmniSeq’s Chief Medical Officer, Roger Klein, MD, JD, FACP. "OmniSeq’s proprietary sample preparation methodologies also allow for minimal tumor tissue input, a critical factor for ensuring NSCLC patient testing can be completed with frequently limited biopsy material available."

OmniSeq’s NGS-based assays provide comprehensive genomic and immune profiling from RNA and DNA to enable oncologists to select the most appropriate therapies or clinical trials for each patient. OmniSeq’s suite of clinical diagnostic tests are offered exclusively by LabCorp to U.S.-based physicians through its Integrated Oncology specialty laboratory and to global biopharmaceutical customers through Covance, LabCorp’s drug development business. OmniSeq Advance is approved by New York State’s Clinical Laboratory Evaluation Program.

Retevmo is indicated for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer, of adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy, or of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trial(s). There is currently no FDA-approved companion diagnostic for Retevmo.

Cancer Prevention Pharmaceuticals Submits
New Drug Application to the FDA for CPP-1X/sul for Treatment of Familial Adenomatous Polyposis

On June 29, 2020 Cancer Prevention Pharmaceuticals, Inc. (CPP), a private biotech company developing novel therapeutics to prevent cancer and other diseases, reported that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for CPP-1X/sul for treatment of adults with familial adenomatous polyposis (FAP) (Press release, Cancer Prevention Pharmaceuticals, JUN 29, 2020, https://www.canprevent.com/wp-content/uploads/2020/06/NDA-Submission-Press-Release-FINAL-2020-06-29.pdf [SID1234563867]). FAP is a rare genetic disease that if left untreated progresses to colorectal cancer in nearly 100% of patients. The clinical development of CPP-1X/sul was designed to establish this fixed dose combination product as a potential pharmaco-preventive drug treatment specifically for FAP patients.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The NDA submission for our lead drug candidate, CPP-1X/sul, represents a significant milestone for FAP patients and their families," said CPP CEO Jeff Jacob. "For most FAP patients, current medical practice involves a lifetime of periodic monitoring as well as highly invasive surgical procedures. If approved, CPP-1X/sul could provide an alternative to surgery for many patients, significantly improving their quality of life."

The FDA’s accelerated approval process allows the agency to approve drugs which address a serious or life-threatening condition based on an intermediate or surrogate endpoint that is likely to predict a clinical long-term benefit. The FDA takes into account such factors as the severity, rarity, or the lack of effective current treatments. The designation has been frequently applied to cancer drugs.

In addition, CPP-1X/sul received an orphan drug designation from the FDA. Among the benefits are eligibility for seven years of market exclusivity upon approval of a drug and tax credits for various costs of clinical testing.

CPP also recently submitted a Marketing Authorization Application (MAA) with the European Union (EU) for CPP-1X/sul for the same indication. The drug received an orphan medicinal product designation for FAP following a favorable assessment provided by the European Medicines Agency’s Committee for Orphan Medicinal Products.

About CPP-1X/sul
CPP-1X/sul is a combination of CPP-1X (eflornithine) and sulindac (CPP-1X/sul). In a clinical trial in patients with large bowel polyps, the CPP-1X/sul combination prevented > 90% subsequent pre-cancerous sporadic adenomas versus placebo. Based on the close biologic similarities with FAP, a Phase 3 pivotal trial compared this same combination to each drug alone (CPP FAP-310).

"With up to four years of treatment, the combination appears to greatly delay the need for major surgeries in the colon, rectum or surgical pouch. We hope that this new drug regimen will soon be available as an adjunct in the management of FAP patients facing large bowel surgery," said Dr. Alfred Cohen, Chief Medical Officer of CPP.

The CPP FAP-310 trial enrolled 171 FAP patients at 17 research institutes in the U.S., Canada, and Europe. It was the largest ever prospective, controlled study performed in FAP and treated patients for up to 48 months, much longer than any other clinical trial in this population. The study was designed to determine if CPP-1X/sul is superior to sulindac or eflornithine as single agents in delaying time to the first occurrence of any FAP-related event, such as surgical removal of the colon, rectum, surgical pouch, duodenum and/or high-risk adenomas. The trial design included FAP patients with varying lower and upper GI disease. CPP-1X/sul did not demonstrate statistical significance in outperforming the single agents in the overall population; however, further analysis of the data showed key differential effects of the agents in the lower vs upper GI anatomy. Focusing on lower GI anatomy (patients with an intact colon, retained rectum or surgical pouch), the data showed statistically significant benefit for CPP-1X/sul vs both single agents (p≤0.02) in delaying surgical events in the lower GI for up to four years. Also, the safety profile of the combination did not significantly differ from that already known for the single agents to support the overall safety assessment of the fixed combination product for long-term therapeutic use.

Oncology Venture signs agreement to out-license two pipeline assets as part of prioritized portfolio strategy

On June 29, 2020 Oncology Venture A/S ("OV" or the "Company") reported that it has signed a definitive agreement out-licensing two clinical pipeline assets, LiPlaCis and 2X-111, to Smerud Medical Research International for further clinical and commercial development (Press release, Oncology Venture, JUN 29, 2020, View Source [SID1234561538]). Under the terms of the agreement, OV will receive regulatory milestone fees of nearly US $30M plus royalties on sales for each drug payable to OV if all the milestones are met . OV also terminated its prior license agreement with Cadila Pharmaceuticals for the development of LiPlaCis in India.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In September 2019, OV announced a significant restructuring, including a new executive management team and a streamlined, prioritized focus on advancing its top three clinical-stage oncology programs towards approval and commercialization. The Company has worked towards establishing partnerships to advance the portfolio while monetizing the value for the Company as part of this ongoing effort.

Smerud Medical Research International AS ("Smerud") is a leading European-based clinical contract research organization (CRO) with expertise in the development of precision cancer drugs. Smerud has previously worked with OV on its LiPlaCis program as well as several other clinical programs. Under their new agreement, Smerud will advance the specific development of LiPlaCis in late stage metastatic breast cancer and 2X-111 in glioblastoma multiforme, in connection with each program’s DRP companion diagnostic.

Steve Carchedi, CEO of Oncology Venture, stated, "Partnering with Smerud allows us to continue development of these two clinical therapeutics together with their DRP companion diagnostics, and to monetize our clinical assets for the benefit of our Company and our shareholders. We remain enthusiastic about the therapeutic potential of both LiPlaCis and 2X-111 together with their DRP companion diagnostics, and we are very pleased to reach this important step towards value creation with these two portfolio assets, and, if all milestones are met, will bring us more than US $30M in regulatory milestone fees plus royalties on future drug sales. Furthermore, this provides us with the opportunity to focus on driving our most advanced programs towards commercialization."

Knut Smerud, CEO of Smerud Medical Research, stated, "Over the past few years, we have been closely involved in advancing the LiPlaCis clinical trial in Denmark through a joint EUROSTARS grant obtained together with OV, and we have seen the benefits that the DRP technology can bring to drug development and, most importantly, to patients. It is not often we get the chance to take over both the full financial and operational responsibility of an ongoing clinical development program, which has already shown very promising interim data, and which addresses the needs of a very high number of patients across the world. Our expectation is that 2X-111 will be just as exciting as LiPlaCis, and therefore we are very enthusiastic about now having the chance to lead the advancement of both of these unique personalized cancer treatments."

The result of pre-clinical trial of ‘PI3K·DNA-PK inhibiting anti-cancer drug’ from Boryung Pharmaceutical

On June 29, 2020 Boryung Pharmaceutical is developing BR101801 (project name BR2002) is an anti-cancer drug which simultaneously inhibits PI3K (γ/δ) and DNA-PK, showed its potential as a treatment in various solid cancer models as well as in blood cancer (Press release, Boryung Pharmaceutical, JUN 29, 2020, View Source [SID1234644864]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Boryung Pharmaceutical unveiled some of the pre-clinical trial results of BR101801 at the annual conference of the American Association for Cancer Research (AACR) (Free AACR Whitepaper), which was held online on the 22nd (local time).

PI3K (phosphoinositide3-kinase) is an enzyme that regulates intracellular signal transduction process and regulates multiple functions such as cell growth, proliferation and differentiation, migration, and survival. As an enzyme that recognizes and repairs DNA damage in cells, DNA-PK helps cancer cells survive despite of DNA damage.

BR101801, solely developed by Boryung Pharmaceutical, is a target anti-cancer agent and cancer immunotherapy agent that simultaneously inhibits PI3K and DNA-PK. In this AACR (Free AACR Whitepaper), Boryung Pharmaceutical released total of 3 posters of which are related to cancer cell death of BR101801: efficacy in monotherapy and combined therapy, efficacy as an cancer immunotherapy drug, ability to inhibit repair factor of cancer cell damage.

Boryung Pharmaceutical not only uses BR101801 alone but also BR101801+ anti PD-1, BR101801+ anti PD-L1, BR101801+ OX40, BR101801+ Doxorubicin in various animal models such as liver cancer, breast cancer, lung cancer and colon cancer models. As a result of combination therapy, efficacy of BR101801 in terms of survival rate and tumor size was confirmed as compared with the control group.

Boryung Pharmaceutical has also conducted a mono and combined efficacy study of BR101801 on cancer cell deaths from peripheral blood mononuclear cells (human PBMCs). Gilead’s Zydelig (Idelalisib), Verastem’s Copiktra (Duvelisib) and other drugs that have been approved as PI3K inhibitors to date have been set as a control group for comparative studies. As a result, it was confirmed that BR101801 showed superior efficacy in killing cancer cells and controlling c-Myc (tumor-inducing gene) compared to the controls from 52 hematological cancer cell lines.

Especially when BR101801 alone is administered, Treg (regulatory T cells) and MDSC (bone marrow-derived suppressor cells), which are immunosuppressive cells, are decreased, and CD8+, which is an immune cell that kills cancer cells, is increased. It has confirmed its effects of a cancer immunotherapy agent. Also, it showed the effect of inhibiting DNA-PK, which is an enzyme involved in recognizing DNA damage in cancer cells and involved in repair, and showed the effect of killing cancer cells.

The researcher team said, "BR101801 has been shown to have the effect of killing cancer cells not only in blood cancer but also in various solid cancers when co-administered with cytotoxic anti-cancer drug or through the radiation."

Boryung Pharmaceutical said BR101801 has been currently undergoing 1st clinical phase for the indication of non-Hochkin’s lymphoma, a type of blood cancer, simultaneously in Korea and in the U.S. since this March.

Novartis receives simultaneous approval for five new products from Japanese Ministry of Health, Labour and Welfare, offering Japanese patients a broad range of novel treatment options

On June 29, 2020 Novartis Pharma K.K. ("Novartis Pharma") reported that the Japanese Ministry of Health, Labour and Welfare (MHLW) simultaneously approved five new treatment options for Japanese patients (Press release, Novartis, JUN 29, 2020, View Source [SID1234561519]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Tabrecta (capmatinib, formerly INC280), an oral MET inhibitor for MET exon 14 skipping (METex14) mutation-positive advanced and/or recurrent unresectable non-small cell lung cancer (NSCLC),
Entresto (sacubitril valsartan sodium hydrate) in chronic heart failure,
Mayzent (siponimod fumaric acid) in secondary progressive MS,
Enerzair (glycopyrronium bromide, indacaterol acetate, mometasone furoate) and
Atectura (indacaterol acetate, mometasone furoate) in different forms of asthma
"The simultaneous approval of five new products is remarkable for Japan and our industry. We are pleased to see that our innovative products gain the support from leading regulatory bodies", said Kazunari Tsunaba, Representative Director and President of Novartis Pharma. "All five medicines are truly novel and transformative treatments and therefore mark an important milestone in our mission to reimagine medicine. I would like to thank our Japanese and global colleagues for all their dedication to make this unprecedented milestone happen."

To date, Novartis has received seven new product approvals in Japan this year. In addition to today’s five approvals, in March, Novartis was granted marketing authorizations for spinal muscular atrophy treatment Zolgensma and for Beovu, an anti-VEGF treatment for wet AMD. These approvals and today’s very unprecedented milestone stand testament to the overall strength of Novartis innovative medicines pipeline and its commitment to ensure patients in Japan have timely access to these life-changing medicines.